• The total number of VTE events across the European countries under study will increase by 15%, from 488,000 in 2016 to 560,000 in 2026.
  • With 55% of VTE events across the European countries under study being  provoked rather than idiopathic, a reduction in VTE events is feasible with prophylaxis among high-risk groups.
  • Similar to the mature markets, about 20% of  VTE events across the European countries under study are recurrent, with the remainder being first-ever events

Table of contents

  • Venous Thromboembolism - Epidemiology - Europe Data
    • Introduction
      • Key Findings
        • Overview
          • VTE Events per 100,000 People of All Ages in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in VTE Events over the Next Ten Years
          • VTE Events in 2016 by Subtype
      • Epidemiology Data
      • Methods
        • Diagnosed Events of VTE
        • VTE Events by Etiology
        • VTE Events by Cancer Association
        • VTE Events by Recurrence
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of VTE
          • Studies Excluded from the Analysis of VTE
        • Risk/Protective Factors
          • Risk/Protective Factors for VTE
        • Bibliography

    Author(s): Ema Rodrigues, DSc, MPH; Emma McFadden, PhD

    Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables.

    She completed her master’s and doctoral degree (MPH, D.Sc.) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.


    Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

    Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.